<DOC>
	<DOCNO>NCT02359045</DOCNO>
	<brief_summary>This study randomize , open-label , cross-over study healthy subject perform single study center . The study divide two part , Part 1 Part 2 . The purpose study compare pharmacokinetics ( PK ) three different prototype capsule formulation ( omega-3-carboxylic acid test formulation ) Epanova® capsule 1000 mg fast condition Part 1 fed condition Part 2 . The result use basis choice formulation pharmaceutical development .</brief_summary>
	<brief_title>Study Healthy Subjects Compare Concentrations Omega-3 Fatty Acids EPA DHA Blood When Delivered Three New Capsules Relation Epanova® Capsule Under Fasting Fed Conditions</brief_title>
	<detailed_description>To assess relative bioavailability different omega-3-carboxylic acid prototype capsule formulation relation Epanova® capsule 1000 mg feed fasted condition .</detailed_description>
	<criteria>Provision sign date write informed consent prior study specific procedure . Healthy male female ( nonchildbearing potential ) subject age 18 55 year suitable vein cannulation repeat venipuncture . Females must negative pregnancy test screen admission clinical unit , must lactate must nonchildbearing potential , confirm screen fulfil one follow criterion : Postmenopausal , define amenorrhea least 12 month follow cessation exogenous hormonal treatment , folliclestimulating hormone ( FSH ) level postmenopausal range . Documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation . Have body mass index ( BMI ) 18.5 29.9 kg/m2 inclusive weigh least 50 kg 100 kg inclusive . History clinically significant disease disorder , opinion investigator , may either put potential subject risk participation study , influence result potential subject 's ability participate study . History presence gastrointestinal , hepatic renal disease , condition know interfere absorption , distribution , metabolism , excretion drug . Current smoker smoke used nicotine product within previous 3 month . Consumption poppy seed within 7 day first administration IMP . Consumption fish within 7 day prior admission clinical unit . Used fish oil , omega3 fatty acid ( EPA and/or DHA ) contain supplement within 1 month admission clinical unit . Have know sensitivity allergy soybean , fish and/or shellfish .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Omega-3-carboxylic acid ,</keyword>
	<keyword>Phase I ,</keyword>
	<keyword>Healthy Subjects ,</keyword>
	<keyword>Pharmacokinetics ,</keyword>
	<keyword>Relative bioavailability</keyword>
</DOC>